The Life Sciences team guided Tango Therapeutics, Inc. (Nasdaq: TNGX) in an underwritten public offering of $690 million of its common stock. All shares in the offering were offered by Tango and included the exercise of the underwriters' option to purchase additional shares.
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
The Goodwin team was led by Marishka DeToy, Katie Hand, Mitch Bloom, Claire Treesh, Lauren Zhang, Li Chang, Cassidy Mertin, Austin Church, Adam DiTullio, Susan Lee, Krupa Zachariah, Dan Karelitz, Catherine McCarty, Ioana Davies, Deborah Birnbach, and Caitlin Tompkins.
For more information, please read the launch press release and pricing press release.